Individualised therapeutic approach to the patient with atypical haemolytic-uraemic syndrome
Atypical haemolytic-uraemic syndrome (aHUS) is a rare disease associated with uncontrolled activation of the alternative complement pathway, leading to thrombotic microangiopathy (TMA). Early diagnosis and treatment with eculizumab, a monoclonal antibody targeting the complement component C5, are cr...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2024-11-01
|
| Serija: | Clinical Medicine |
| Teme: | |
| Online pristup: | http://www.sciencedirect.com/science/article/pii/S1470211824054356 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|